Related by context. All words. (Click for frequent words.) 74 lopinavir r 72 HCV RESPOND 2 71 LEXIVA r 70 #mg BID [001] 70 ritonavir boosted 68 active comparator 68 alfa 2a 67 lopinavir r arm 67 BARACLUDE ® 67 ribavirin RBV 67 mg qd 67 mcg kg 67 TMC# C# 67 Tipranavir 67 pegylated interferon alfa 2a 67 mg QD 67 ACTEMRA TM 66 plus dexamethasone 66 #mg QD [001] 66 #mg QD [002] 66 mg BID 66 REYATAZ R 66 HCV SPRINT 66 8mg/kg 66 amprenavir 66 achieved ACR# 66 q8h 66 peginterferon alfa 2b 66 rapid virologic response 66 CIMZIA TM 66 PREZISTA r 66 administered subcutaneously 66 Peg IFN 66 mg/m2 IV 66 plus COPEGUS 66 relapsed MM 65 R# #mg BID 65 virus HCV protease inhibitor 65 Randomized Phase 65 mcg QD 65 q#h 65 telaprevir dosed 65 plus Copegus R 65 plus prednisone 65 Pegasys ® 65 sustained virologic response 65 HBeAg seroconversion 65 plus methotrexate 65 fosamprenavir 65 unfractionated heparin UFH 65 COMBIVIR 65 log# copies mL 65 mcg albinterferon alfa 2b 65 ritonavir boosted atazanavir 65 Oral Fingolimod 65 clodronate 65 #mg BID [003] 64 Virologic 64 SVR# 64 VELCADE melphalan 64 placebo dexamethasone 64 FOLFIRI 64 IFN α 64 Trial Evaluating 64 PEG Interferon alfa 64 multicenter multinational 64 EURIDIS 64 oxycodone CR 64 pegylated interferon alpha 64 PEGINTRON TM 64 atazanavir sulfate 64 LPV r 64 HBeAg negative patients 64 adefovir 64 piperacillin tazobactam 64 Phase 2b Clinical Trial 64 Betaferon R 64 telaprevir dosing 64 Randomized Double Blind 64 Pegasys plus Copegus 64 Acetate Rectal Suppositories 64 LEXIVA 64 #mg q8h 64 cEVR 64 metastatic castration resistant 64 Engerix B 64 ug kg 64 alpha 2a 64 mg TID 64 pegylated interferon alfa 2b 63 Median PFS 63 plus ribavirin 63 humanized interleukin 6 63 #mg/m# [002] 63 TO AVOID PREGNANCY WHILE 63 Pivotal Phase 63 mcg BID 63 mg kg dose 63 non inferiority 63 IFN alfa 63 Chronic Hepatitis C 63 efavirenz EFV 63 Meets Primary Endpoint 63 tocilizumab 63 ABC/3TC 63 FOLFOX 63 FEMALES SHOULD BE ADVISED 63 randomized multicenter 63 -#.# log# 63 REMICADE monotherapy 63 REYATAZ r arm 63 μg dose 63 ug dose 63 QD dosing 63 abacavir lamivudine 63 Sandostatin R 63 multicenter placebo controlled 63 comparator arm 63 peginterferon alfa 2a 63 alfa 2b 63 Peginterferon 63 undetectable HCV RNA 63 trastuzumab Herceptin R 63 microgram kg 63 sunitinib Sutent ® 63 mRCC 63 peginterferon alfa 2a Pegasys 63 adalimumab Humira 63 PREZISTA ritonavir 63 achieved sustained virologic 63 evaluating tivozanib 63 evaluable subjects 63 ALVESCO 63 dexamethasone Decadron 63 tenofovir emtricitabine 63 Peginterferon Alfa 2a 63 posaconazole 62 atazanavir ritonavir 62 TMC# r 62 Initiate Phase 62 #mg/m# [001] 62 candesartan cilexetil 62 Sustained Virologic Response 62 Adalimumab 62 GOUT 62 PROCTOCORT ® Suppository Hydrocortisone 62 mg RDEA# 62 Telbivudine 62 TAXUS ATLAS 62 dosing cohorts 62 mapatumumab 62 PegIFN 62 By JENNIFER LEARN 62 Pegasys R 62 APTIVUS r 62 CLARITY study 62 PEG IFN 62 mg ustekinumab 62 Folfox 62 RECORD1 62 Pivotal Phase III 62 lamivudine 3TC 62 virologic response 62 TDF FTC 62 CIMZIA TM certolizumab pegol 62 Monotherapy 62 mcg dose 62 Demonstrate Significant 62 Darunavir 62 tipranavir r 62 Aflibercept 62 Aptivus ® 62 Lupuzor ™ 62 achieved CCyR 62 mg/m2 dose 62 Phase III Clinical Trial 62 multicenter randomized 62 adjunctive placebo 62 tacrolimus capsules 62 median PFS 62 ARCOXIA 62 abacavir sulfate lamivudine 62 ALT normalization 62 treatment naïve genotype 62 BRIM3 62 #mg/day [002] 62 Pegasys peginterferon alfa 2a 62 daily Infergen 62 FOLFOX6 62 ritonavir boosted lopinavir 62 oral rivaroxaban 62 PRECiSE 62 Randomized Double blind 62 FOLPI 62 ATACAND 62 Pooled Analysis 62 novel VDA molecule 61 virologic failures 61 Relapsed Multiple Myeloma 61 Dasatinib 61 azilsartan medoxomil 61 TRANSFORMS 61 virologic failure 61 Initiated Phase 61 metastatic hormone refractory 61 dasatinib Sprycel ® 61 SCH # 61 docetaxel chemotherapy 61 mg m² 61 ceftazidime 61 CIMZIA ™ 61 antiretroviral naïve 61 nucleoside naive 61 Phase IIb Trial 61 cetuximab Erbitux R 61 pegylated interferon 61 monotherapy 61 VIRAMUNE 61 RGT arm 61 Mg Usa 61 oral allopurinol 61 Protease Inhibitor 61 tenofovir disoproxil fumarate 61 treatment naive genotype 61 Study Evaluating 61 infliximab monotherapy 61 telaprevir pegylated interferon 61 HBeAg positive patients 61 mg q#h 61 doxorubicin cyclophosphamide 61 etanercept 61 protease inhibitor PI 61 PEGASYS ® 61 Phase 2a Clinical Trial 61 lopinavir ritonavir Kaletra 61 tipranavir ritonavir 61 chlorambucil 61 lamivudine monotherapy 61 dapagliflozin plus 61 HCV genotype 1 61 5 FU leucovorin 61 SPRYCEL ® 61 3mg/kg 61 ULORIC 61 Traficet EN 61 blinded randomized placebo controlled 61 Omacetaxine 61 Randomized Phase II 61 INCB# [003] 61 sustained virological response 61 Myocardial Infarction Study 61 Fludara 61 CCX# B 61 naïve HCV 61 BRIM2 61 pegylated liposomal doxorubicin 61 Flu Cy 61 receiving INTRON 61 phase IIb clinical 61 mg/m2 61 investigational protease inhibitor 61 peg interferon 61 trimethoprim sulfamethoxazole 61 Viread Emtriva 61 Naive Patients 61 achieved statistical significance 61 stage IIIb IV 61 azathioprine monotherapy 61 Cream USP 1 61 REYATAZ ® 61 LUX Lung 61 placebo controlled Phase 61 interferon alfa 2a 61 rosuvastatin #mg 61 tipranavir 61 Prolongs Survival 61 fluticasone furoate 61 ACR# response 61 HIV RNA 61 nilotinib 61 APTIVUS 61 Hormone Refractory Prostate Cancer 61 imatinib therapy 61 #mg ritonavir 61 CR nPR 61 Tarceva TM 61 PegIFN RBV 61 lenalidomide Revlimid R 61 cyclophosphamide methotrexate 61 FOLFOX4 alone 61 potent CYP#A# inhibitors 60 mg administered orally 60 multicentre randomized 60 retapamulin 60 subcutaneously administered 60 Xelox 60 familial amyloidotic polyneuropathy FAP 60 Treatment Naive Patients 60 achieved PASI 60 FluCAM 60 LymphoStat B belimumab 60 Sprycel dasatinib 60 mg orally 60 Copegus ® 60 Controlled Trial 60 lixisenatide 60 lopinavir ritonavir 60 Multicenter Phase 60 TMC# [001] 60 darunavir r 60 #mg/kg [002] 60 #mg/#mg 60 Phase 2b Study 60 #.#g/day 60 oral FTY# 60 entecavir 60 Randomized Double Blind Placebo 60 Phase III Trial 60 azacitidine 60 Relapsing Remitting Multiple Sclerosis 60 febrile neutropenia 60 log# IU mL 60 infliximab 60 4mg/kg 60 PRADAXA #mg 60 Sorafenib HCC Assessment 60 NSABP B 60 ® emtricitabine 60 Enoxaparin 60 decitabine 60 CCyR 60 Randomized Phase III 60 recurrent glioblastoma multiforme 60 severe neutropenia 60 nevirapine Viramune 60 linezolid 60 nelfinavir 60 nab paclitaxel 60 placebo PBO 60 Single Dose 60 phase IIa 60 FOLFOX4 60 CML CP 60 peg IFN 60 VFEND 60 lopinavir 60 seropositive patients 60 NEVO 60 Peginterferon alfa 2b 60 -#.# log# copies mL 60 highly emetogenic 60 relapsed CLL 60 HBeAg positive 60 certolizumab 60 Doxil ® 60 Hycamtin ® 60 Randomised 60 Copegus ribavirin 60 daunorubicin 60 tenofovir FTC 60 mg q8h 60 teriflunomide 60 Durezol 60 carboplatin paclitaxel 60 mGluR5 negative 60 multicenter Phase 60 AZT zidovudine Retrovir 60 certolizumab pegol 60 Sapacitabine 60 HCV Protease Inhibitor 60 insulin detemir 60 ascending dose 60 lamivudine 60 mg subcutaneously 60 peginterferon alfa 60 HBeAg negative 60 DURATION 60 CTAP# Capsules 60 mg/m2/day 60 low dose cytarabine 60 interferon ribavirin 60 lumbar spine BMD 60 Linagliptin 60 doripenem 60 Prospective Randomized Trial 60 Randomized Controlled 60 peginterferon alfa 2a #KD 60 voriconazole 60 mg Lucentis 60 Phase Ib clinical 60 mg/# hr 60 #mg BID [002] 60 postmenopausal osteoporotic women 60 interferon alfa 60 PROMACTA 60 5 Fluorouracil 60 angiographic outcomes 60 low dose ritonavir 60 Forodesine HCl 60 INCB# [001] 60 achieved sustained virological 60 undetectable HBV DNA 60 Platelet Inhibition 60 docetaxel Taxotere ® 60 sunitinib 60 Epoetin Alfa 60 octreotide LAR 60 Double Blind Placebo 60 dose cohorts 60 SORT OUT 60 YERVOY 60 Relapsing Multiple Sclerosis 59 CRESTOR #mg 59 Randomized Study 59 inhalations twice 59 prospective randomized placebo 59 LANTUS R 59 Phase III placebo controlled 59 ertapenem 59 EGFR TKI 59 #.#mg/dL 59 amoxicillin clavulanate 59 dacarbazine 59 plus prednisone prednisolone 59 5-FU/LV 59 eltrombopag 59 Taxotere ® 59 PRE SURGE 59 desvenlafaxine succinate 59 ACR# ACR# 59 FUSILEV enhances 59 cells uL 59 Phase 2b Trial 59 adriamycin 59 -#.# mg dL [002] 59 Demonstrated Significant 59 QTcF 59 #mg/day [001] 59 AVONEX ® 59 docetaxel Taxotere R 59 Q2W 59 MCyR 59 Tiotropium 59 Complicated Skin 59 REMINYL ® 59 plus gemcitabine 59 dose cytarabine 59 Adjuvant Treatment 59 experienced virologic failure 59 Severe Sepsis 59 Elitek 59 nucleoside analog 59 prucalopride 59 Xeloda ® 59 Pharmacokinetic parameters 59 neutropenia dehydration dyspnea 59 Placebo Controlled 59 elotuzumab 59 Trandolapril 59 antiviral efficacy 59 Tocilizumab 59 transcriptase inhibitor NNRTI 59 Nilotinib 59 multicenter randomized placebo controlled 59 Epivir 59 ACR# responses 59 adalimumab 59 somatostatin analog 59 non splenectomized 59 evaluating REVLIMID 59 VIRAMUNE XR 59 PEGylated anti 59 talabostat 59 Achieves Primary Endpoint 59 subcutaneous enoxaparin 59 CHAMPION PCI 59 colesevelam HCl 59 CANCIDAS 59 mitoxantrone 59 PEG interferon 59 tenofovir Viread 59 Investigational Compound 59 Peginterferon alfa 2a 59 rimonabant #mg 59 weekly CSBMs 59 BENICAR 59 nitazoxanide 59 placebo fluoxetine 59 salmeterol fluticasone 59 AEGR 59 goserelin 59 mcg linaclotide 59 dalteparin 59 Novel Oral 59 Indacaterol 59 fumarate 59 mCi kg 59 oral vancomycin 59 erlotinib Tarceva ® 59 Parathyroid Hormone 59 Index CDAI 59 Pivotal Trial 59 XIENCE V demonstrated 59 Non Responders 59 subcutaneous doses 59 3TC lamivudine Epivir 59 lamivudine refractory patients 59 alefacept 59 Cethromycin 59 PRN FDA Approves 59 interferon gamma 1b 59 fasting plasma glucose FPG 59 hour bronchodilation 59 ZD# [001] 59 log# reduction 59 Rating Scale MADRS 59 Combination REOLYSIN R 59 CLL SLL 59 Anticancer Activity 59 Newly Diagnosed Multiple Myeloma 59 Amrubicin 59 antiretroviral naive 59 lispro 59 genotype 1b 59 EQUATE OB 59 vicriviroc 59 pegylated interferon peg IFN 59 phase IIIb 59 Sustained virologic response 59 degarelix 59 MabCampath 59 bendamustine 59 #μg [002] 59 viral kinetics 59 rilpivirine 59 cabazitaxel 59 events AEs 59 dose regimens 59 XIENCE V PROMUS Stent 59 Prograf ® 59 biochemical relapse 59 brivaracetam 59 copies mL 59 plus OBT 59 II Clinical Trial 59 atazanavir 59 Ozarelix 59 oral prodrug 59 Pharmacokinetic Study 59 betamethasone dipropionate #.# 59 Mg Uk 59 PEGylated interferon beta 1a 59 PEGylated Fab fragment 59 COPEGUS 59 Alkeran 59 BCIRG 59 Prostate AdenoCarcinoma Treatment 59 sorafenib Nexavar 59 pegylated interferon alpha 2a 59 dextromethorphan quinidine 59 gout flares 59 HGS ETR1 59 antibody MAb 59 inhibitor RG# 59 Antiviral Activity 59 NCCTG N# 59 Vicriviroc 59 randomized #:#:# 59 plasma HCV RNA 59 Non inferiority 59 sorafenib tablets 58 miconazole Lauriad ® 58 safinamide 58 complete cytogenetic response 58 Blind Placebo Controlled 58 saline placebo 58 Hsp# Inhibitor 58 Plus Ribavirin 58 adefovir treated 58 ongoing Phase 1b 58 cell lymphoma CTCL 58 alpha 2b 58 CAMMS# 58 PREZISTA r arm 58 mitoxantrone plus 58 Randomized Evaluation 58 cilostazol 58 pomalidomide 58 refractory chronic lymphocytic 58 Demonstrates Potent 58 paclitaxel cisplatin 58 Phase Ib II 58 Laquinimod 58 HCV genotypes 58 Polymerase Inhibitor 58 TAXUS Liberte Long 58 Crohn Disease Activity 58 imipenem 58 Golimumab 58 leuprorelin 58 RE LY ® 58 PEG Interferon lambda 58 subanalysis 58 VICTRELIS 58 Capsules CII 58 mg doses 58 Is Well Tolerated 58 prospectively defined 58 double blinded randomized 58 stage IIIB 58 INVIRASE 58 laboratory abnormalities 58 dosed orally 58 TAXUS p value 58 Camptosar ® 58 randomized Phase III 58 mm Stent 58 anakinra 58 tigecycline 58 #/#mg 58 Roche Pegasys 58 genotype 1a 58 randomized controlled Phase 58 ELOXATIN 58 diabetic neuropathic pain 58 boosted protease inhibitor 58 Hepsera 58 Celsentri Selzentry 58 treatment naļve 58 controlled multicenter 58 virologically suppressed 58 irbesartan 58 Remission Maintenance 58 Phase 2a trial 58 cytidine nucleoside analog 58 phase IIa clinical 58 forodesine 58 First Patient Dosed 58 Interferon beta 1b 58 multicenter Phase III 58 mITT population 58 annualized relapse 58 PEG INTRON R 58 GSK# [001] 58 lanthanum carbonate 58 darunavir ritonavir 58 Metastatic Colorectal Cancer 58 Ocrelizumab 58 primary hypercholesterolemia 58 cytologically confirmed 58 MIVI III 58 mcg Albuferon 58 NXL# 58 NATRECOR R 58 dose escalation clinical 58 Androxal TM 58 REVIVE Diabetes 58 assessing T DM1 58 carbamazepine phenobarbital phenytoin rifampin 58 RANK Ligand inhibitor 58 TPV r 58 PROCTOCORT R Cream Hydrocortisone 58 Primary endpoints 58 ribavirin USP 58 de novo kidney transplant 58 Patency 58 sunitinib malate 58 Nephrol Dial Transplant 58 plus GP IIb 58 raltegravir 58 Previously Untreated 58 ORENCIA ® 58 Double Blind Randomized 58 cisplatin vinorelbine 58 fosbretabulin 58 intermittent dosing 58 Teriflunomide 58 CYP#A# substrate 58 COZAAR 58 ExTRACT TIMI 58 nucleotide analog 58 AVOREN 58 AIR CF1 58 chronic HCV genotype 58 Hemodialysis Patients 58 Pharmacokinetics PK 58 HCV Genotype 58 rilonacept 58 GAMMAGARD 58 tolvaptan 58 recurrent GBM 58 budesonide pMDI 58 Adenoma Prevention 58 Patients Treated With 58 NRTI 58 peginterferon 58 huC# DM4 58 CLL8 58 FTY# fingolimod 58 weekly subcutaneous injections 58 Multicenter 58 peginterferon alpha 2a 58 evaluable 58 Phase IIIb clinical 58 insulin glargine rDNA origin 58 LEVAQUIN ® 58 mg BID dose 58 Acute Ischemic Stroke 58 blinded placebo controlled 58 oral antidiabetic medication 58 bone marrow reticulin deposition 58 discontinuations due 58 FOLPI regimen 58 Antitumor Activity 58 Vfend 58 Lung Cancer Trial 58 Placebo Controlled Trial 58 estramustine 58 double blinded placebo 58 Rebif ® 58 FluCAM arm 58 controlled multicenter Phase 58 viral kinetic 58 Blinatumomab 58 Treated Patients 58 Phase III Pivotal Trial 58 darunavir 58 Ziprasidone 58 morphometric vertebral fractures 58 JAK Inhibitor 58 Pivotal Study 58 Phase III Clinical Trials 58 registrational Phase 58 DASISION 58 Nebulized 58 ONTARGET 58 primary efficacy endpoints 58 zolmitriptan 58 Val HeFT 58 mg hydrochlorothiazide 58 Potent Antiviral Activity 58 Rivaroxaban 58 mg kg belimumab 58 seroprotection 58 dasatinib 58 REMICADE ® 58 evaluating Actimmune 58 delafloxacin 58 AIR CF2 58 STRIDE PD 58 Pharmacokinetic 58 Dose Ranging Study 58 Abiraterone Acetate 58 Phase #/#a 58 Multiple Ascending Dose 58 Anti Tumor Activity 58 budesonide foam 58 imatinib 58 ORACLE MS 58 MIRCERA 58 Placebo Controlled Study 58 baminercept 58 cells mcL 58 temsirolimus 58 IIIa inhibitor 58 CALGB 58 leukopenia 58 DU #b 58 ARIXTRA 58 Kidney Int 58 Epratuzumab 58 ribavirin therapy 58 RE LY 58 relapsed myeloma 58 rapid virological response 58 DAPT 58 randomized multicenter trial 58 ara C 58 Capecitabine 58 Valsartan 58 ARIKACE 58 elagolix 58 MADRS score 58 candesartan 58 timolol 58 Events MACE 58 μmol L 58 hyperphenylalaninemia HPA due 58 mycophenolate mofetil 58 leukemia AML 58 Previously Treated 58 doxorubicin docetaxel 57 infusional 5-FU/LV 57 Vitro Activity 57 Castration Resistant Prostate Cancer 57 Completes Patient Enrollment 57 liposome injection 57 Copegus 57 Initiate Phase III 57 generalized edema 57 noninferiority 57 pan HDAC inhibitor 57 GW# [003] 57 mcg kg REBETOL 57 Posaconazole 57 TLUS 57 receiving golimumab 57 Navelbine 57 pimecrolimus cream 57 gemcitabine carboplatin 57 tazobactam 57 corticosteroid dose 57 beta 1a 57 BARACLUDE R 57 DOXIL 57 Patients Treated 57 indinavir Crixivan 57 YONDELIS 57 cisplatin gemcitabine 57 Raptiva r 57 null responder HCV 57 #mg doses [002] 57 valacyclovir 57 Cutaneous T 57 BOLDER II 57 tolterodine ER 57 RLAI 57 virologic 57 lamivudine zidovudine 57 splenectomized 57 COPAXONE R 57 seroconversion 57 Study Showed 57 ARB telmisartan 57 bosentan 57 undetectable virus HCV 57 valopicitabine 57 Pred Forte 57 Controlled Study 57 intravenous dosing 57 pyrazinamide 57 pyrimidine nucleoside analog 57 Free Survival PFS 57 APPRAISE 57 events SAEs 57 tapentadol ER 57 melphalan prednisone 57 telbivudine 57 phase Ib clinical 57 antiviral activity 57 mg simvastatin 57 CK # plasma concentrations 57 Fluorouracil 57 receptor tyrosine kinase inhibitor 57 beta2 agonist 57 oral levofloxacin 57 advanced metastatic renal 57 relapsed refractory multiple myeloma 57 lumiliximab 57 Rebetol 57 multicenter randomized controlled 57 atypical Hemolytic Uremic Syndrome 57 Ambulatory Blood Pressure 57 phase Ib 57 Myelodysplastic Syndrome MDS 57 radezolid 57 nicardipine 57 Solid Tumors criteria 57 Kaplan Meier analysis 57 receiving prophylactic anticoagulation 57 FOLFIRI alone 57 #.#/#.# mmHg [001] 57 Demonstrates Sustained 57 metastatic CRC 57 NVA# 57 Viread Emtriva Sustiva 57 Clinical Trial Results 57 octreotide acetate 57 oral diclofenac 57 PREZISTA rtv 57 fluvastatin 57 low dose dexamethasone 57 Psoriasis Area 57 standard chemotherapy regimen 57 ancrod 57 Stent Restenosis 57 ACTEMRA 57 apremilast 57 imetelstat 57 Phase Ib IIa 57 #ug [001] 57 SPIRIT FIRST 57 μg kg 57 EGFR HER2 57 interferon beta 1b 57 Jevtana 57 Completes Enrollment 57 interferon alfa 2b 57 mg/# hours 57 nadroparin 57 mg/# h 57 Inhalation Aerosol 57 Enzastaurin 57 Moxifloxacin 57 cariprazine 57 efavirenz emtricitabine 57 Vidofludimus 57 microbiological eradication 57 #mg ATC 57 AGILECT ® 57 Telithromycin 57 fluticasone salmeterol 57 Follicular Lymphoma 57 Median progression 57 Response Evaluation Criteria 57 refractory NSCLC 57 biologic DMARD 57 Betaferon ® 57 dose ritonavir 57 Ranolazine 57 edoxaban 57 Phase 1b 57 Pegylated Interferon 57 Omacetaxine mepesuccinate 57 bortezomib 57 rizatriptan 57 PRTX 57 HCV RNA 57 efavirenz Sustiva 57 fostamatinib 57 complete cytogenetic 57 Metastatic Renal Cell Carcinoma 57 Certolizumab 57 ascending doses 57 multicenter randomized double 57 FOLFOX6 chemotherapy regimen 57 ng dL 57 trough FEV1 57 PRoFESS 57 S/GSK# 57 ARCALYST ® 57 inflammatory lesions 57 RAPAFLO 57 neurologic progression 57 indinavir 57 dose cohort 57 rFSH 57 MAGE A3 ASCI 57 HbA1c levels 57 Navelbine ® 57 Irinotecan 57 tacrolimus ointment 57 Boceprevir 57 mg m 57 bicalutamide 57 ® lenalidomide 57 EPIVIR 57 heavily pretreated 57 mcg doses 57 Intervention Effectiveness 57 Phase IIb Clinical Trial 57 Patients Receiving 57 vincristine doxorubicin 57 Montgomery Asberg Depression 57 FAME Study 57 p = NS 57 myelodysplastic myeloproliferative diseases 57 multicenter phase 57 APTIVUS R 57 nucleoside reverse transcriptase inhibitor 57 receiving VICTRELIS 57 PASI scores 57 fluorouracil 57 secondary efficacy endpoints 57 multicenter Phase II 57 metastatic castrate resistant 57 chemotherapy gemcitabine 57 q#d 57 mg dosed twice 57 Phase 2a Trial 57 ibandronate 57 Fulvestrant 57 1mg 2mg 57 metastatic renal cell carcinoma 57 virological response 57 Demonstrates Positive 57 imatinib Gleevec ® 57 leukemia CLL 57 STELARA TM 57 Pegintron 57 stage IIIb 57 inhaled corticosteroid ICS 57 TAXUS Stent 57 Randomized Clinical Trial 57 Statistically Significant 57 saquinavir 57 NNRTI 57 RAPTIVA 57 mitoxantrone chemotherapy